Ben Bailiff

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

Full Donor T Cell Chimerism Predicts Transplant Outcomes In High Risk AML But Not In Intermediate Risk AML After a T-Deplete Alemtuzumab Conditioned Transplant

Amy Gudger, Vidhya Murthy, Duncan Murray, Ben Bailiff et autres

Abstract Reduced intensity conditioning (RIC) T-deplete regimens are now widely used as a platform to deliver a potentially curative T cell mediated graft-versus-leukaemia (GVL) effect in patients with haematological malignancies. T cell chimerism has been shown to correlate with the risk of …

gb (code pays fourni par la source)

Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?

Ben Bailiff, Neil Phillips, Vidhya Murthy, Lynn Bratby et autres

Abstract High dose melphalan conditioned APBSCT after induction therapy is thestandard of carefor patients with myeloma with good performance status. Busy haematology units are in the lookout for safe and effective strategies to hasten neutrophil engraftment, decrease inpatient stay and ease financial …

gb (code pays fourni par la source)